Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
National Cancer Institute (NCI)
Active, not recruiting ID
For more information, see NCT02568566
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
Human Papillomavirus-Related Carcinoma
Yi Zeng

See list of participating sites